(Original title: Fosun Pharma: Fubitai bivalent vaccine arrives in Hong Kong and Macao and will start covering Omicron virus mutants)
Securities Times e-company news, according to Fosun Pharma, on November 26, Fosun Pharma (600196.SH; 02196.HK) announced that the first batch of approximately 770,000 doses of Fubitai original strain/Omicron BA mutant strain. The bivalent vaccine (30 micrograms per dose) (“Fubitai Bivalent Vaccine”) was delivered to China’s Hong Kong Special Administrative Region on November 25. Fubitai bivalent vaccine can be used as a fourth booster injection for eligible people 12 years of age and older, and the third dose can be used for people who are recovered. On November 26, the Government Health Office of the Macao Special Administrative Region said that in response to the outbreak of the new variant of the Omicron coronavirus, the Government of the Macao Special Administrative Region purchased the bivalent BioNTech for the new variant of the Omicron coronavirus BA.4/5 The mRNA vaccine and Fubitai mRNA vaccine, which can be vaccinated for children aged 6 months to 4 years old, have all arrived in Macao and will start providing vaccinations after the completion of the vaccine delivery process. The Fubita bivalent vaccine is the iteration and supplement of Fubita BNT162b2, which is already on the market.
